BioNTech SE

Welcome to BioNTech's first quarter 2025 earnings call. I would like to hand the call over to Michael Horowitz, Director, Investor Relations. Please go ahead.

Thank you. Good morning and good afternoon.

Thank you for joining BioNTech's first quarter 2025 earnings call. As a reminder, the slides we will be using during this call and the corresponding press release we issued this morning can be found in the Investor Relations section of our website. On the next slide, you will see our forward-looking statements disclaimer. Additional information about these statements and other risks are described in our filings with the U.S. Securities and Exchange Commission. Forward-looking statements on this call are subject to significant risks and uncertainties and seek only as of the date of this conference call. We undertake no obligation to update or revise any of these statements. On slide three, you can find the agenda for today's call. Today, I am joined by the following members of BioNTech's management team. Ugar Zaheen, chief executive officer and co-founder, Azam Torechi, Chief Medical Officer and Co-Founder, Jens Holstein, Chief Financial Officer, and Ryan Richardson, Chief Strategy Officer. With this, I would like to hand the call over to Ugar.